换肤

成都先导

i问董秘

A03737

主营介绍

  • 主营业务：

    提供药物早期发现阶段的研发服务以及新药研发项目转让

  • 产品类型：

    DEL筛选服务、DEL库定制服务、化学合成服务、新药研发项目转让、其他

  • 产品名称：

    DEL筛选服务 、 DEL库定制服务 、 化学合成服务 、 新药研发项目转让 、 其他

  • 经营范围：

    药物研发并提供技术咨询、技术转让、技术服务。(依法须经批准的项目，经相关部门批准后方可开展经营活动)

主营构成分析

报告期
报告期
{"2019-06-30":{"YYSR":{"2":[["DEL\u7b5b\u9009\u670d\u52a1","5787.60"],["DEL\u5e93\u5b9a\u5236\u670d\u52a1","3990.15"],["\u5316\u5b66\u5408\u6210\u670d\u52a1","448.32"],["\u5176\u4ed6\u670d\u52a1","254.04"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",215.02]],"3":[["\u7f8e\u56fd","8632.27"],["\u97e9\u56fd","884.56"],["\u65e5\u672c","686.47"],["\u5176\u4ed6","318.71"],["\u4e2d\u56fd","173.12"]]},"YYCB":{"2":[["DEL\u7b5b\u9009\u670d\u52a1","900.73"],["DEL\u5e93\u5b9a\u5236\u670d\u52a1","827.89"],["\u5316\u5b66\u5408\u6210\u670d\u52a1","340.67"],["\u5176\u4ed6\u670d\u52a1","10.58"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",9.63]],"3":[["\u7f8e\u56fd",""],["\u97e9\u56fd",""],["\u65e5\u672c",""],["\u5176\u4ed6",""],["\u4e2d\u56fd",""]]},"LRBL":{"2":[["DEL\u7b5b\u9009\u670d\u52a1","56.79"],["DEL\u5e93\u5b9a\u5236\u670d\u52a1","36.75"],["\u5316\u5b66\u5408\u6210\u670d\u52a1","1.25"],["\u5176\u4ed6\u670d\u52a1","2.83"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",2.39]],"3":[["\u7f8e\u56fd",""],["\u97e9\u56fd",""],["\u65e5\u672c",""],["\u5176\u4ed6",""],["\u4e2d\u56fd",""]]}},"2019-03-31":{"YYSR":{"2":[["DEL\u5e93\u5b9a\u5236\u670d\u52a1","2560.81"],["DEL\u7b5b\u9009\u670d\u52a1","2149.67"],["\u5316\u5b66\u5408\u6210\u670d\u52a1","197.54"],["\u5316\u5408\u7269\u7ed3\u6784\u77e5\u8bc6\u4ea7\u6743\u8f6c\u8ba9\u8d39","166.90"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0.39]],"3":[["\u7f8e\u56fd","4072.32"],["\u97e9\u56fd","546.50"],["\u65e5\u672c","274.48"],["\u5176\u4ed6","140.48"],["\u4e2d\u56fd","41.52"]]},"YYCB":{"2":[["DEL\u5e93\u5b9a\u5236\u670d\u52a1","437.68"],["DEL\u7b5b\u9009\u670d\u52a1","464.12"],["\u5316\u5b66\u5408\u6210\u670d\u52a1","152.40"],["\u5316\u5408\u7269\u7ed3\u6784\u77e5\u8bc6\u4ea7\u6743\u8f6c\u8ba9\u8d39","3.83"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0.25]],"3":[["\u7f8e\u56fd",""],["\u97e9\u56fd",""],["\u65e5\u672c",""],["\u5176\u4ed6",""],["\u4e2d\u56fd",""]]},"LRBL":{"2":[["DEL\u5e93\u5b9a\u5236\u670d\u52a1","52.85"],["DEL\u7b5b\u9009\u670d\u52a1","41.96"],["\u5316\u5b66\u5408\u6210\u670d\u52a1","1.12"],["\u5316\u5408\u7269\u7ed3\u6784\u77e5\u8bc6\u4ea7\u6743\u8f6c\u8ba9\u8d39","4.06"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0.0035]],"3":[["\u7f8e\u56fd",""],["\u97e9\u56fd",""],["\u65e5\u672c",""],["\u5176\u4ed6",""],["\u4e2d\u56fd",""]]}},"2018-12-31":{"YYSR":{"2":[["DEL\u7b5b\u9009\u670d\u52a1","7901.90"],["DEL\u5e93\u5b9a\u5236\u670d\u52a1","4865.12"],["\u5316\u5b66\u5408\u6210\u670d\u52a1","1239.61"],["\u5176\u4ed6\u670d\u52a1","985.57"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",127.4]],"3":[["\u7f8e\u56fd","12418.54"],["\u5176\u4ed6","1210.11"],["\u65e5\u672c","834.48"],["\u4e2d\u56fd","655.07"],["\u97e9\u56fd","1.40"]]},"YYCB":{"2":[["DEL\u7b5b\u9009\u670d\u52a1","1046.37"],["DEL\u5e93\u5b9a\u5236\u670d\u52a1","848.59"],["\u5316\u5b66\u5408\u6210\u670d\u52a1","670.89"],["\u5176\u4ed6\u670d\u52a1","46.31"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",9.32]],"3":[["\u7f8e\u56fd",""],["\u5176\u4ed6",""],["\u65e5\u672c",""],["\u4e2d\u56fd",""],["\u97e9\u56fd",""]]},"LRBL":{"2":[["DEL\u7b5b\u9009\u670d\u52a1","54.85"],["DEL\u5e93\u5b9a\u5236\u670d\u52a1","32.14"],["\u5316\u5b66\u5408\u6210\u670d\u52a1","4.55"],["\u5176\u4ed6\u670d\u52a1","7.52"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",0.94]],"3":[["\u7f8e\u56fd",""],["\u5176\u4ed6",""],["\u65e5\u672c",""],["\u4e2d\u56fd",""],["\u97e9\u56fd",""]]}}}
{"YYSR":{"chartWrap2":[{"name":"DEL\u7b5b\u9009\u670d\u52a1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[5787.6,2149.67,7901.9],"columnData":[54.11,42.36,52.26],"unit":["5787.60\u4e07","2149.67\u4e07","7901.90\u4e07"]},{"name":"DEL\u5e93\u5b9a\u5236\u670d\u52a1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[3990.15,2560.81,4865.12],"columnData":[37.31,50.46,32.18],"unit":["3990.15\u4e07","2560.81\u4e07","4865.12\u4e07"]},{"name":"\u5316\u5b66\u5408\u6210\u670d\u52a1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[448.32,197.54,1239.61],"columnData":[4.19,3.89,8.2],"unit":["448.32\u4e07","197.54\u4e07","1239.61\u4e07"]},{"name":"\u5176\u4ed6\u670d\u52a1","timeData":["2019-06-30","2018-12-31"],"lineData":[254.04,985.57],"columnData":[2.38,6.52],"unit":["254.04\u4e07","985.57\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[215.02,0.39,127.4],"columnData":[2.01,0.01,0.84],"unit":["215.02\u4e07","3900.00","127.40\u4e07"]},{"name":"\u5316\u5408\u7269\u7ed3\u6784\u77e5\u8bc6\u4ea7\u6743\u8f6c\u8ba9\u8d39","timeData":["2019-03-31"],"lineData":[166.9],"columnData":[3.29],"unit":["166.90\u4e07"]}],"chartWrap3":[{"name":"\u7f8e\u56fd","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[8632.27,4072.32,12418.54],"columnData":[80.71,80.24,82.14],"unit":["8632.27\u4e07","4072.32\u4e07","1.24\u4ebf"]},{"name":"\u97e9\u56fd","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[884.56,546.5,1.4],"columnData":[8.27,10.77,0.0093],"unit":["884.56\u4e07","546.50\u4e07","1.40\u4e07"]},{"name":"\u65e5\u672c","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[686.47,274.48,834.48],"columnData":[6.42,5.41,5.52],"unit":["686.47\u4e07","274.48\u4e07","834.48\u4e07"]},{"name":"\u5176\u4ed6","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[318.71,140.48,1210.11],"columnData":[2.98,2.77,8],"unit":["318.71\u4e07","140.48\u4e07","1210.11\u4e07"]},{"name":"\u4e2d\u56fd","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[173.12,41.52,655.07],"columnData":[1.62,0.82,4.33],"unit":["173.12\u4e07","41.52\u4e07","655.07\u4e07"]}]},"YYCB":{"chartWrap2":[{"name":"DEL\u7b5b\u9009\u670d\u52a1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[900.73,464.12,1046.37],"columnData":[43.11,43.86,39.92],"unit":["900.73\u4e07","464.12\u4e07","1046.37\u4e07"]},{"name":"DEL\u5e93\u5b9a\u5236\u670d\u52a1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[827.89,437.68,848.59],"columnData":[39.62,41.36,32.37],"unit":["827.89\u4e07","437.68\u4e07","848.59\u4e07"]},{"name":"\u5316\u5b66\u5408\u6210\u670d\u52a1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[340.67,152.4,670.89],"columnData":[16.3,14.4,25.59],"unit":["340.67\u4e07","152.40\u4e07","670.89\u4e07"]},{"name":"\u5176\u4ed6\u670d\u52a1","timeData":["2019-06-30","2018-12-31"],"lineData":[10.58,46.31],"columnData":[0.51,1.77],"unit":["10.58\u4e07","46.31\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[9.63,0.25,9.32],"columnData":[0.46,0.02,0.36],"unit":["9.63\u4e07","2500.00","9.32\u4e07"]},{"name":"\u5316\u5408\u7269\u7ed3\u6784\u77e5\u8bc6\u4ea7\u6743\u8f6c\u8ba9\u8d39","timeData":["2019-03-31"],"lineData":[3.83],"columnData":[0.36],"unit":["3.83\u4e07"]}],"chartWrap3":[{"name":"\u7f8e\u56fd","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u97e9\u56fd","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u65e5\u672c","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u4e2d\u56fd","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]}]},"LRBL":{"chartWrap2":[{"name":"DEL\u7b5b\u9009\u670d\u52a1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[56.79,41.96,54.85],"columnData":[56.79,41.96,54.85],"unit":["56.79\u4e07","41.96\u4e07","54.85\u4e07"]},{"name":"DEL\u5e93\u5b9a\u5236\u670d\u52a1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[36.75,52.85,32.14],"columnData":[36.75,52.85,32.14],"unit":["36.75\u4e07","52.85\u4e07","32.14\u4e07"]},{"name":"\u5316\u5b66\u5408\u6210\u670d\u52a1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[1.25,1.12,4.55],"columnData":[1.25,1.12,4.55],"unit":["1.25\u4e07","1.12\u4e07","4.55\u4e07"]},{"name":"\u5176\u4ed6\u670d\u52a1","timeData":["2019-06-30","2018-12-31"],"lineData":[2.83,7.52],"columnData":[2.83,7.52],"unit":["2.83\u4e07","7.52\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[2.39,0,0.94],"columnData":[2.39,0,0.94],"unit":["2.39\u4e07","35.00","9400.00"]},{"name":"\u5316\u5408\u7269\u7ed3\u6784\u77e5\u8bc6\u4ea7\u6743\u8f6c\u8ba9\u8d39","timeData":["2019-03-31"],"lineData":[4.06],"columnData":[4.06],"unit":["4.06\u4e07"]}],"chartWrap3":[{"name":"\u7f8e\u56fd","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u97e9\u56fd","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u65e5\u672c","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u5176\u4ed6","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]},{"name":"\u4e2d\u56fd","timeData":["2019-06-30","2019-03-31","2018-12-31"],"lineData":[0,0,0],"columnData":[0,0,0],"unit":["0.00","0.00","0.00"]}]}}

营业收入 X

单位（%） 单位（万元）
注：通常在中报、年报时披露　
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按产品 DEL筛选服务 5787.60万 54.11% 900.73万 43.11% 56.79% 84.44%
DEL库定制服务 3990.15万 37.31% 827.89万 39.62% 36.75% 79.25%
化学合成服务 448.32万 4.19% 340.67万 16.30% 1.25% 24.01%
其他服务 254.04万 2.38% 10.58万 0.51% 2.83% 95.84%
化合物结构知识产权转让费 215.02万 2.01% 9.63万 0.46% 2.39% 95.52%
按地区 美国 8632.27万 80.71% - - - -
韩国 884.56万 8.27% - - - -
日本 686.47万 6.42% - - - -
其他 318.71万 2.98% - - - -
中国 173.12万 1.62% - - - -

董事会经营评述

　　（一）营业收入分析
　　1、报告期内经营逻辑分析
　　（1）全球药物CRO行业市场规模较快增长
　　药物研发CRO行业可分为临床前CRO和临床试验CRO两大主要类别，其中临床前CRO又可以细分为药物发现CRO与临床前研究CRO，药物发现CRO包括药物筛选、化学合成、先导化合物优化等。中国药物发现CRO服务市场规模虽然整体较小，但近年来随着我国新药研发环境的逐步成熟，研发投入不断增加，我国药物发现CRO市场规模呈快速增长态势，2011-2018年年复合增长率达到24.8%，属于CRO行业增长最快的细分领域。作为新药研发最前端的环节，药物发现在新药研发中具有举足轻重的地位。目前我国药物发现CR... 查看全部▼

　　（一）营业收入分析
　　1、报告期内经营逻辑分析
　　（1）全球药物CRO行业市场规模较快增长
　　药物研发CRO行业可分为临床前CRO和临床试验CRO两大主要类别，其中临床前CRO又可以细分为药物发现CRO与临床前研究CRO，药物发现CRO包括药物筛选、化学合成、先导化合物优化等。中国药物发现CRO服务市场规模虽然整体较小，但近年来随着我国新药研发环境的逐步成熟，研发投入不断增加，我国药物发现CRO市场规模呈快速增长态势，2011-2018年年复合增长率达到24.8%，属于CRO行业增长最快的细分领域。作为新药研发最前端的环节，药物发现在新药研发中具有举足轻重的地位。目前我国药物发现CRO企业全国约一百家左右，整体呈现龙头企业引领，中小企业创新特色发展局面。预计至2020年中国药物发现的市场规模将达到220亿元，2018至2022年复合增长率约为30%。
　　（2）公司DEL库规模及质量不断提升满足了市场及客户的需求
　　发行人作为药物发现领域具有技术特色的研发服务企业，其DEL技术是目前全球范围内药物筛选领域最为前沿和热点的技术方向之一。一方面，随着商业化程度的提高，该技术正在被药企和生物技术公司所广泛接受和应用；另一方面，随着公司DEL库技术水平的提高，DEL库规模不断扩大，目前已建成亚洲首家、全球最大的DNA编码小分子实体化合物库之一，公司因此而获得的DEL筛选服务收入和DEL库定制服务收入得以快速增长。
　　2、营业收入构成及变动分析
　　2016年度、2017年度、2018年度及2019年1-3月，公司营业收入分别为1,642.91万元、5,321.87万元、15,119.60万元和5,075.30万元。2016-2018年度，公司营业收入年均复合增长率达203.36%，整体呈现良好的增长趋势。
　　2016-2018年度及2019年1-3月，公司主营业务收入主要来源于DEL筛选服务、DEL库定制服务、化学合成服务。上述三块主要业务具体情况如下：
　　（1）DEL筛选服务
　　2016-2018年度及2019年1-3月，公司DEL筛选服务收入为776.91万元、4,169.24万元、7,901.90万元和2,149.67万元，占营业收入比例分别为47.29%、78.34%、52.26%和42.36%，是公司重要收入来源之一。2016-2018年度，公司DEL筛选服务业务年均复合增长率达218.92%，整体保持良好的增长趋势。公司DEL筛选服务收入保持持续增长主要原因系凭借全球领先的DNA编码化合物库技术，发行人得到了全球跨国制药企业及国际知名生物技术公司认可，陆续与包括辉瑞、强生、默沙东、赛诺菲、武田制药等公司建立了合作关系，为其提供DEL筛选服务。
　　目前先导化合物中心拥有多名海外及国内的生物化学专业博士作为业务带头人，专业的团队确保了公司能够持续为客户提供高质量技术研发服务，先导化合物中心人均创收呈逐年增长趋势。
　　（2）DEL定制库服务
　　发行人利用其独特的DNA编码化合物库设计、合成技术及前期积累的丰富经验，可为全球大型药物公司和生物技术公司设计并合成客户专属的DEL库，合作伙伴可根据自身的药物领域、研究方向、生物靶点特点及成药性结构经验等，与发行人共同进行专属化合物库的设计，发行人负责DNA编码化合物库的具体实验步骤及方案实施。
　　DEL的设计、合成与筛选，是药物发现领域创新性的热门方法之一，并已证明其商业价值，故发行人提供的DEL定制库服务得到了全球大型跨国药企的青睐。2017年度、2018年度及2019年1-3月，DEL定制库服务产生的收入分别为256.24万元、4,865.12万元和2,560.81万元，占营业收入比例分别达到4.81%、32.18%和50.46%，DEL定制库服务产生的收入占比逐步提高，是公司未来重要的收入增长点。报告期内，发行人定制库服务收入主要来自于辉瑞、默沙东和Forma。
　　（3）化学合成服务
　　公司拥有一个在药物筛选和药物化学合成方面先进的技术平台，配备有性能优良的生物学和化学实验设备，具有非常强的科研能力。基于DNA编码化合物库，发行人可对外提供高质量的小分子化合物及核酸相关合成服务，具体主要包括核酸合成、核酸修饰、核苷类化合物合成及特殊化学结构的化合物定制合成等。
　　2016-2018年度及2019年1-3月，化学合成服务产生收入分别为839.92万元、875.01万元、1,239.61万元和197.54万元。
　　（4）化合物结构知识产权转让费
　　若客户对于DEL筛选结果满意，则客户会选择受让化合物结构知识产权，发行人与客户签署License Letter并收取License Fee，2018年度与2019年1季度该部分收入分别为127.40万元及166.90万元，收入占比较小。
　　（5）其他服务
　　2018年度，发行人向客户进行部分筛选技术、数据处理分析技术的培训，以便客户能够独立完成基本的筛选和数据分析实验，2018年度该项业务产生收入827.76万元。除上述外，报告期内，其他服务金额较小。
　　3、主营业务收入的地区分布分析
　　公司的主要客户来自于国内外知名药企，其中，海外客户收入占比90%以上。
　　2016年度、2017年度、2018年度和2019年1-3月分别达到93.25%、90.72%、95.67%和99.18%，随着公司研发的持续投入和经验积累，公司市场竞争力不断增强，业务也进入快速拓展期，业务地区分布越来越广泛。
　　4、主营业务收入的季度分析
　　报告期内，公司主营业务收入不存在明显的季节性变化。 收起▲

同花顺个股页面 | F10论坛 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。